Biocryst Pharmaceutical’s Revenue by Segment (2016-2022)

This statistic highlights Biocryst Pharmaceutical’s revenue by segment from Q1 2016 onwards, split across Collaborative and other Research and Development, Product Sales and Royalty Revenue segments.

Biocryst Pharmaceutical’s Revenue by Segment

(All figures in millions, except percentages)

Biocryst Pharmaceuticals’ revenue in Q3 2020 was $6.1 million, which multiplied by almost 6 times in Q3 2021 and rose to $40.99 million. Quarterly, the company observed a revenue growth of 17.2% as compared to $34.96 million in Q2 2021 to $40.99 million in Q3 2021.

Further, the revenue can be bifurcated into the following segments:

Collaborative and other Research and Development

There are various third-party firms or organizations, with which Biocryst has license agreements or collaborations. Apart from these, the company even has Research and Development agreements with multiple government entities for the manufacture of medicines or drugs. This is known as the Collaborative and other Research Development segment.

Trends Observed

• This segment earned a revenue of $1.53 million in Q3 2021, which consisted of 4% of the company’s total revenue.
• In Q3 2020, the revenue from this segment was $3.37 million and contributed 55% to the total revenue; but by Q3 2021, it fell by approx. 54.5%.
• Quarterly, there was a growth as the revenue increased by 9% from $1.4 million in Q2 2021.

Product Sales

Product sales refer to the selling of medicine or oral drugs and other commodities provided by the firm.

Trends Observed

• The Product Sales segment accounted for 95% of the company’s total revenue in Q3 2021, worth $39.14 million.
• In Q3 2020, this segment incurred a revenue of $2.48 million, which went up by more than 10 times in Q3 2021, to $39.14 million.
• On a QoQ basis, the segment observed a growth of approximately 17% as compared to $33.43 million in Q2 2021.

Royalty Revenue

This segment includes the revenue earned by Biocryst Pharmaceuticals from patents of various medicines/drugs the company produces, with other pharmaceutical companies like Shinogi or Green Cross.

Trends Observed

• Royalty Revenue segments revenue in Q3 2021 was $0.32 million, which was 1% of the total revenue.
• On a YoY basis, the revenue went up by 25% from $0.25 million in Q3 2020.
• Quarterly, in Q2 2021, the segment revenue was $0.13 million which multiplied approximately 1.5 times to $0.32 million in Q3 2021.

About the Company

Found in 1986, BioCryst Pharmaceuticals Inc. is a US-based pharmaceutical company. It is headquartered in North Carolina and focuses on producing oral drugs for serious and rare diseases or illness. The firm masters in clinical development, regulatory affairs and drug discovery. With this, they are even progressing at advancing such clinical programs and generation of new compounds from the company’s discovery engine.

Did you like Biocryst Pharmaceutical’s revenue by segment statistic?

Access more such KPI data points and segment financials on thousands of US stocks, with Business Quant.

You can get started here.